Company Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial.
The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 253 |
| CEO | Ms. Sarah Boyce |
Contact Details
Address: J.h. Oortweg 21 2133 Ch Leiden, P7 00000 Netherlands | |
| Phone | 31 0 713320100 |
| Website | aviditybiosciences.com |
Stock Details
| Ticker Symbol | RNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001574111 |
| CUSIP Number | 05370A108 |
| ISIN Number | US05370A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Co-Founder and Chairman |
| Sarah Boyce | President, Chief Executive Officer and Director |
| Michael F. MacLean | Chief Financial and Chief Business Officer |
| Dr. W. Michael Flanagan Ph.D. | Chief Scientific and Technical Officer |
| Teresa McCarthy | Chief Human Resources Officer |
| Eric B. Mosbrooker | Chief Strategy Officer |
| Prof. Mark E. Davis | Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers |
| Dr. Frank P. McCormick Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Geoffrey M. Grande C.F.A. | Vice President of Investor Relation and Corporate Communication |
| Dr. John W. Wallen III | Vice President of Intellectual Property, General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 16, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2016 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 8, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 30, 2015 | 20-F | Annual and transition report of foreign private issuers |
| Mar 23, 2015 | 15-12B | Securities registration termination |
| Feb 17, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2015 | 6-K | Report of foreign issuer |
| Feb 12, 2015 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 11, 2015 | 25 | Filing |
| Feb 10, 2015 | 6-K | Report of foreign issuer |